Pgen stock forecast short interest in PGEN remains low

Short interest in PGEN remains low, enhancing the bullish case for the stock. PGEN stock forecast scenarios from quant models suggest that if revenue guidance improves, price could retest previous highs set earlier this year. Reveal the 233 hidden gems among our US High Growth Tech and AI Stocks screener with a single click here. Precigen (PGEN) reported better-than-expected first-quarter earnings and is making strides toward commercializing its lead asset, PRGN-2012, for recurrent respiratory papillomatosis. The FDA has granted priority review to the company’s Biologics License Application (BLA) for PRGN-2012, with a decision expected by August 2025. Financially, while the company has faced increased research and development costs linked to PRGN-2012, it ended 2024 with a cash position that extends its runway into 2026. Analysts maintain a positive outlook on the stock, citing its promising pipeline and readiness for a prospective product launch. Market sentiment gauges for PGEN stock forecast show cautious optimism, with hedge fund activity rising slightly. The overall biotech sector valuation multiples are compressing, but companies with strong IP portfolios tend to outperform.